NCT02678338View on ClinicalTrials.gov

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

February 28, 2019

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Hu5F9-G4

Trial Locations (5)

Unknown

University Hospital of Wales, Cardiff

St. James University Hospital, Leeds

The Royal Liverpool University Hospital, Liverpool

The Christie NHS Foundation Trust, Manchester

Churchill Hospital, Oxford

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Gilead Sciences

INDUSTRY